Skip to content
Pramoxine
Pramosone (pramoxine) is a small molecule pharmaceutical. Pramoxine was first approved as Pramosone on 1982-01-01. It is used to treat contact dermatitis, fissure in ano, hemorrhoids, pain, and pruritus in the USA.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
digestive system diseasesD004066
cardiovascular diseasesD002318
skin and connective tissue diseasesD017437
signs and symptoms pathological conditionsD013568
psychological phenomenaD011579
musculoskeletal and neural physiological phenomenaD055687
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
Brand Name
Status
Last Update
dch calaspray itch reliefOTC monograph not final2023-06-08
epifoamANDA2020-09-18
pramosoneANDA2018-12-18
proctofoamANDA2018-02-13
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
contact dermatitis—D003877L25
fissure in anoHP_0012390D005401K60.2
hemorrhoidsEFO_0009552D006484K64
painEFO_0003843D010146R52
pruritusHP_0000989D011537L29
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
C: Cardiovascular system drugs
— C05: Vasoprotectives
— C05A: Agents for treatment of hemorrhoids and anal fissures for topical use
— C05AD: Local anesthetics for treatment of hemorrhoids and anal fissures for topical use
— C05AD07: Pramocaine
D: Dermatologicals
— D04: Antipruritics, incl. antihistamines, anesthetics, etc.
— D04A: Antipruritics, incl. antihistamines, anesthetics, etc.
— D04AB: Anesthetics for topical use
— D04AB07: Pramocaine
HCPCS
No data
Clinical
Clinical Trials
50 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Type 1 diabetes mellitusD003922EFO_0001359E1044551129
Type 2 diabetes mellitusD003924EFO_0001360E11—323210
HypoglycemiaD007003HP_0001943E16.2———1—1
Weight gainD015430HP_0004324———1—1
SchizophreniaD012559EFO_0000692F20———1—1
Psychotic disordersD011618F20.81———1—1
Indications Phases 3
No data
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
ObesityD009765EFO_0001073E66.9—8——19
OverweightD050177E66.3—4———4
Diabetes mellitusD003920EFO_0000400E08-E1311———1
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Alzheimer diseaseD000544EFO_0000249F031————1
Cognitive dysfunctionD060825G31.841————1
Squamous cell carcinomaD0022941————1
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
HyperglycemiaD006943HP_0003074R73.9————22
Migraine without auraD020326EFO_0005296G43.0————11
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common namePRAMOXINE
INNpramocaine
Description
Pramocaine is a member of the class of morpholines that is morpholine substituted at the nitrogen atom by a 3-(4-butoxyphenoxy)propyl group. It has a role as a local anaesthetic. It is a member of morpholines and an aromatic ether.
Classification
Small molecule
Drug class—
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
CCCCOc1ccc(OCCCN2CCOCC2)cc1
Identifiers
PDB—
CAS-ID140-65-8
RxCUI34347
ChEMBL IDCHEMBL1198
ChEBI ID8357
PubChem CID4886
DrugBankDB09345
UNII ID068X84E056 (ChemIDplus, GSRS)
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 205 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
2,496 adverse events reported
View more details